What is Rivfloza®? Unpacking the RNAi Therapy for PH1
•
1 min read
In September 2023, the FDA approved Rivfloza® (nedosiran), marking a significant milestone for patients with primary hyperoxaluria type 1 (PH1), a rare genetic disorder characterized by excessive oxalate production. As an innovative RNA interference (RNAi) therapy, Rivfloza works to reduce the burden of oxalate by targeting the source of its overproduction in the liver.
